COMMUNIQUÉS West-GlobeNewswire
-
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
06/07/2026 -
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
06/07/2026 -
Amplia Announces Changes to Board’s Leadership Roles
06/07/2026 -
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
06/07/2026 -
Catheter Precision, Inc. Announces Issuance of Two Key Patents
06/07/2026 -
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
06/07/2026 -
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
06/07/2026 -
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
06/07/2026 -
ThreeSixty Journalism Kicks Off Multimedia Storytelling Institute Summer Program for Local High School Students
06/07/2026 -
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
06/07/2026 -
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
06/07/2026 -
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
06/07/2026 -
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
06/07/2026 -
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
06/07/2026 -
Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
06/07/2026 -
Pluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd
06/07/2026 -
La recommandation du CMUH fait passer le TECVAYLI®▼ (teclistamab) de Johnson & Johnson, associé au daratumumab, au rang de traitement conventionnel potentiel pour le myélome multiple récidivant ou réfractaire
06/07/2026 -
Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential
06/07/2026 -
Canada Diagnostic Centres, a Novacap Portfolio Company, Announces Acquisition of Shift Imaging
06/07/2026
Pages